Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q3 FY25 results · Oct–Dec 2024
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,010.41 crore and net profit of ₹66.31 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,010.41 | — | — | 1,033.09 | −2.2% |
| Other income | 14.56 | — | — | 13.47 | +8.1% |
| Total income | 1,024.97 | — | — | 1,046.56 | −2.1% |
| Profit before tax | 91.05 | — | — | 91.59 | −0.6% |
| Net profit for the period | 66.31 | — | — | 66.65 | −0.5% |
| Attributable to shareholders of the company | 65.18 | — | — | 65.21 | −0.0% |
| EPS, basic (₹) | 4.26 | — | — | 4.37 | −2.5% |
| Net margin (%) | 6.6 | — | 6.5 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 337.41 | — | — | 328.35 | +2.8% |
| Other income | 33.84 | — | — | 32.12 | +5.3% |
| Total income | 371.25 | — | — | 360.47 | +3.0% |
| Profit before tax | 54.89 | — | — | 61.62 | −10.9% |
| Net profit for the period | 41.17 | — | — | 50.37 | −18.3% |
| EPS, basic (₹) | 2.69 | — | — | 3.38 | −20.4% |
| Net margin (%) | 12.2 | — | 15.3 |
Consolidated
- Filed with BSE
- 06 Feb 2025, 18:27 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2025, 18:27 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE